Selected research
Industry Research
In-Vitro Cancer Diagnostics Industry Research Report 2026
Market perspective
The global In-Vitro Cancer Diagnostics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the In-Vitro Cancer Diagnostics market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the In-Vitro Cancer Diagnostics market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the In-Vitro Cancer Diagnostics market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of In-Vitro Cancer Diagnostics include Abbott Laboratories, Beckman Coulter, Epigenomics AG, MDx Health Quest Diagnostics, Randox Laboratories, R-Biopharm AG, Signature Diagnostics, Amoy Diagnostics Co.,Ltd. and Daan Gene, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global In-Vitro Cancer Diagnostics market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to In-Vitro Cancer Diagnostics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
In-Vitro Cancer Diagnostics Market by Company
Abbott Laboratories
Beckman Coulter
Epigenomics AG
MDx Health Quest Diagnostics
Randox Laboratories
R-Biopharm AG
Signature Diagnostics
Amoy Diagnostics Co.,Ltd.
Daan Gene
Fosun Pharma
Novogene
Burning Rock
Geneseeq
Siemens Healthcare
In-Vitro Cancer Diagnostics Segment by Type
Instruments
Reagents and Kits
In-Vitro Cancer Diagnostics Segment by Application
Laboratories
Hospitals
Others
In-Vitro Cancer Diagnostics Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global In-Vitro Cancer Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of In-Vitro Cancer Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of In-Vitro Cancer Diagnostics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of In-Vitro Cancer Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Instruments
- Reagents and Kits
Applications
- Laboratories
- Hospitals
- Others
Companies covered
- Abbott Laboratories
- Beckman Coulter
- Epigenomics AG
- MDx Health Quest Diagnostics
- Randox Laboratories
- R-Biopharm AG
- Signature Diagnostics
- Amoy Diagnostics Co.,Ltd.
- Daan Gene
- Fosun Pharma
- Novogene
- Burning Rock
- Geneseeq
- Siemens Healthcare
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 In-Vitro Cancer Diagnostics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Instruments
- 2.2.3 Reagents and Kits
- 2.3 In-Vitro Cancer Diagnostics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Laboratories
- 2.3.3 Hospitals
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 In-Vitro Cancer Diagnostics Breakdown Data by Type
- 3.1 Global In-Vitro Cancer Diagnostics Historic Market Size by Type (2021-2026)
- 3.2 Global In-Vitro Cancer Diagnostics Forecasted Market Size by Type (2027-2032)
4 In-Vitro Cancer Diagnostics Breakdown Data by Application
- 4.1 Global In-Vitro Cancer Diagnostics Historic Market Size by Application (2021-2026)
- 4.2 Global In-Vitro Cancer Diagnostics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global In-Vitro Cancer Diagnostics Market Perspective (2021-2032)
- 5.2 Global In-Vitro Cancer Diagnostics Growth Trends by Region
- 5.2.1 Global In-Vitro Cancer Diagnostics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 In-Vitro Cancer Diagnostics Historic Market Size by Region (2021-2026)
- 5.2.3 In-Vitro Cancer Diagnostics Forecasted Market Size by Region (2027-2032)
- 5.3 In-Vitro Cancer Diagnostics Market Dynamics
- 5.3.1 In-Vitro Cancer Diagnostics Industry Trends
- 5.3.2 In-Vitro Cancer Diagnostics Market Drivers
- 5.3.3 In-Vitro Cancer Diagnostics Market Challenges
- 5.3.4 In-Vitro Cancer Diagnostics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top In-Vitro Cancer Diagnostics Players by Revenue
- 6.1.1 Global Top In-Vitro Cancer Diagnostics Players by Revenue (2021-2026)
- 6.1.2 Global In-Vitro Cancer Diagnostics Revenue Market Share by Players (2021-2026)
- 6.2 Global In-Vitro Cancer Diagnostics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of In-Vitro Cancer Diagnostics Head Office and Area Served
- 6.4 Global In-Vitro Cancer Diagnostics Players, Product Type & Application
- 6.5 Global In-Vitro Cancer Diagnostics Manufacturers Established Date
- 6.6 Global In-Vitro Cancer Diagnostics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America In-Vitro Cancer Diagnostics Market Size (2021-2032)
- 7.2 North America In-Vitro Cancer Diagnostics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America In-Vitro Cancer Diagnostics Market Size by Country (2021-2026)
- 7.4 North America In-Vitro Cancer Diagnostics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe In-Vitro Cancer Diagnostics Market Size (2021-2032)
- 8.2 Europe In-Vitro Cancer Diagnostics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe In-Vitro Cancer Diagnostics Market Size by Country (2021-2026)
- 8.4 Europe In-Vitro Cancer Diagnostics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific In-Vitro Cancer Diagnostics Market Size (2021-2032)
- 9.2 Asia-Pacific In-Vitro Cancer Diagnostics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific In-Vitro Cancer Diagnostics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific In-Vitro Cancer Diagnostics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America In-Vitro Cancer Diagnostics Market Size (2021-2032)
- 10.2 South America In-Vitro Cancer Diagnostics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America In-Vitro Cancer Diagnostics Market Size by Country (2021-2026)
- 10.4 South America In-Vitro Cancer Diagnostics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa In-Vitro Cancer Diagnostics Market Size (2021-2032)
- 11.2 Middle East & Africa In-Vitro Cancer Diagnostics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa In-Vitro Cancer Diagnostics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa In-Vitro Cancer Diagnostics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Abbott Laboratories
- 12.1.1 Abbott Laboratories Company Information
- 12.1.2 Abbott Laboratories Business Overview
- 12.1.3 Abbott Laboratories Revenue in In-Vitro Cancer Diagnostics Business (2021-2026)
- 12.1.4 Abbott Laboratories In-Vitro Cancer Diagnostics Product Portfolio
- 12.1.5 Abbott Laboratories Recent Developments
- 12.2 Beckman Coulter
- 12.2.1 Beckman Coulter Company Information
- 12.2.2 Beckman Coulter Business Overview
- 12.2.3 Beckman Coulter Revenue in In-Vitro Cancer Diagnostics Business (2021-2026)
- 12.2.4 Beckman Coulter In-Vitro Cancer Diagnostics Product Portfolio
- 12.2.5 Beckman Coulter Recent Developments
- 12.3 Epigenomics AG
- 12.3.1 Epigenomics AG Company Information
- 12.3.2 Epigenomics AG Business Overview
- 12.3.3 Epigenomics AG Revenue in In-Vitro Cancer Diagnostics Business (2021-2026)
- 12.3.4 Epigenomics AG In-Vitro Cancer Diagnostics Product Portfolio
- 12.3.5 Epigenomics AG Recent Developments
- 12.4 MDx Health Quest Diagnostics
- 12.4.1 MDx Health Quest Diagnostics Company Information
- 12.4.2 MDx Health Quest Diagnostics Business Overview
- 12.4.3 MDx Health Quest Diagnostics Revenue in In-Vitro Cancer Diagnostics Business (2021-2026)
- 12.4.4 MDx Health Quest Diagnostics In-Vitro Cancer Diagnostics Product Portfolio
- 12.4.5 MDx Health Quest Diagnostics Recent Developments
- 12.5 Randox Laboratories
- 12.5.1 Randox Laboratories Company Information
- 12.5.2 Randox Laboratories Business Overview
- 12.5.3 Randox Laboratories Revenue in In-Vitro Cancer Diagnostics Business (2021-2026)
- 12.5.4 Randox Laboratories In-Vitro Cancer Diagnostics Product Portfolio
- 12.5.5 Randox Laboratories Recent Developments
- 12.6 R-Biopharm AG
- 12.6.1 R-Biopharm AG Company Information
- 12.6.2 R-Biopharm AG Business Overview
- 12.6.3 R-Biopharm AG Revenue in In-Vitro Cancer Diagnostics Business (2021-2026)
- 12.6.4 R-Biopharm AG In-Vitro Cancer Diagnostics Product Portfolio
- 12.6.5 R-Biopharm AG Recent Developments
- 12.7 Signature Diagnostics
- 12.7.1 Signature Diagnostics Company Information
- 12.7.2 Signature Diagnostics Business Overview
- 12.7.3 Signature Diagnostics Revenue in In-Vitro Cancer Diagnostics Business (2021-2026)
- 12.7.4 Signature Diagnostics In-Vitro Cancer Diagnostics Product Portfolio
- 12.7.5 Signature Diagnostics Recent Developments
- 12.8 Amoy Diagnostics Co.,Ltd.
- 12.8.1 Amoy Diagnostics Co.,Ltd. Company Information
- 12.8.2 Amoy Diagnostics Co.,Ltd. Business Overview
- 12.8.3 Amoy Diagnostics Co.,Ltd. Revenue in In-Vitro Cancer Diagnostics Business (2021-2026)
- 12.8.4 Amoy Diagnostics Co.,Ltd. In-Vitro Cancer Diagnostics Product Portfolio
- 12.8.5 Amoy Diagnostics Co.,Ltd. Recent Developments
- 12.9 Daan Gene
- 12.9.1 Daan Gene Company Information
- 12.9.2 Daan Gene Business Overview
- 12.9.3 Daan Gene Revenue in In-Vitro Cancer Diagnostics Business (2021-2026)
- 12.9.4 Daan Gene In-Vitro Cancer Diagnostics Product Portfolio
- 12.9.5 Daan Gene Recent Developments
- 12.10 Fosun Pharma
- 12.10.1 Fosun Pharma Company Information
- 12.10.2 Fosun Pharma Business Overview
- 12.10.3 Fosun Pharma Revenue in In-Vitro Cancer Diagnostics Business (2021-2026)
- 12.10.4 Fosun Pharma In-Vitro Cancer Diagnostics Product Portfolio
- 12.10.5 Fosun Pharma Recent Developments
- 12.11 Novogene
- 12.11.1 Novogene Company Information
- 12.11.2 Novogene Business Overview
- 12.11.3 Novogene Revenue in In-Vitro Cancer Diagnostics Business (2021-2026)
- 12.11.4 Novogene In-Vitro Cancer Diagnostics Product Portfolio
- 12.11.5 Novogene Recent Developments
- 12.12 Burning Rock
- 12.12.1 Burning Rock Company Information
- 12.12.2 Burning Rock Business Overview
- 12.12.3 Burning Rock Revenue in In-Vitro Cancer Diagnostics Business (2021-2026)
- 12.12.4 Burning Rock In-Vitro Cancer Diagnostics Product Portfolio
- 12.12.5 Burning Rock Recent Developments
- 12.13 Geneseeq
- 12.13.1 Geneseeq Company Information
- 12.13.2 Geneseeq Business Overview
- 12.13.3 Geneseeq Revenue in In-Vitro Cancer Diagnostics Business (2021-2026)
- 12.13.4 Geneseeq In-Vitro Cancer Diagnostics Product Portfolio
- 12.13.5 Geneseeq Recent Developments
- 12.14 Siemens Healthcare
- 12.14.1 Siemens Healthcare Company Information
- 12.14.2 Siemens Healthcare Business Overview
- 12.14.3 Siemens Healthcare Revenue in In-Vitro Cancer Diagnostics Business (2021-2026)
- 12.14.4 Siemens Healthcare In-Vitro Cancer Diagnostics Product Portfolio
- 12.14.5 Siemens Healthcare Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst